InsidersTradesSigma
Athenex, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Athenex, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Athenex, Inc. has logged 170 insider filings. The latest transaction was filed on 8 May 2023 (Attribution). Among the most active insiders: LAU JOHNSON YIU NAM. The full history is openly available.
170
Insider Decl.
0
Thresholds
€515,805
28 ops.
Buy Volume
·
0 ops.
Sell Volume
27Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 May 2023
Declarations170 total
3,603 shares@ US$1.361.3% of flowCommon StockSEC:0001209191-23-027948:0
8,382 shares@ US$1.361.9% of flowCommon StockSEC:0001209191-23-027951:0
368 shares@ US$1.363.2% of flowCommon StockSEC:0001209191-23-027942:0
383 shares@ US$1.3053.2% of flowCommon StockSEC:0001209191-23-025394:0
6,513 shares@ US$1.30518.3% of flowCommon StockSEC:0001209191-23-025413:0
5,747 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025401:0
3,642 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025397:0
8,813 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025410:0
2,300 shares@ US$1.30519.2% of flowCommon StockSEC:0001209191-23-025408:0
8,736 shares@ US$1.3051.9% of flowCommon StockSEC:0001209191-23-025405:0
3,755 shares@ US$1.3051.3% of flowCommon StockSEC:0001209191-23-025403:0
4,017 shares@ US$1.221.3% of flowCommon StockSEC:0001209191-23-024010:0
9,344 shares@ US$1.221.9% of flowCommon StockSEC:0001209191-23-024005:0
410 shares@ US$1.223.2% of flowCommon StockSEC:0001209191-23-024016:0
360 shares@ US$1.393.2% of flowCommon StockSEC:0001209191-23-021233:0
3,525 shares@ US$1.391.3% of flowCommon StockSEC:0001209191-23-021230:0
8,201 shares@ US$1.391.9% of flowCommon StockSEC:0001209191-23-021224:0
5,519 shares@ US$1.941.8% of flowCommon StockSEC:0001209191-23-018191:0
2,526 shares@ US$1.941.4% of flowCommon StockSEC:0001209191-23-018198:0
258 shares@ US$1.943.3% of flowCommon StockSEC:0001209191-23-018206:0
1,788 shares@ US$2.741.4% of flowCommon StockSEC:0001209191-23-013263:0
625 sharesCommon StockSEC:0001209191-23-013223:0
182 shares@ US$2.743.3% of flowCommon StockSEC:0001209191-23-013246:0
1,591 shares@ US$2.740.7% of flowCommon StockSEC:0001209191-23-013259:0
25 of 170 declarations
About Athenex, Inc.
Athenex, Inc. (ticker: ATNX) was a U.S.-listed biopharmaceutical company whose common stock traded on the Nasdaq Global Select Market, making it a NYSE/NASDAQ-style U.S. public-market name for investors following SEC disclosures and insider activity. The company was historically headquartered in Buffalo, New York, United States. It was formed in November 2003 as Kinex Pharmaceuticals LLC, began operations in February 2004, and later converted into a Delaware corporation in December 2012 before taking the Athenex name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai)) From a business-model standpoint, Athenex was built as an oncology-focused biotech with a mix of research, development, manufacturing, and specialty commercialization. Its core scientific narrative centered on oral taxane delivery through the Orascovery platform, including oral paclitaxel and encequidar, alongside other technology platforms such as Src kinase inhibition, TCR-T cell therapy, and arginine deprivation approaches. The company’s historical pipeline also included candidates such as KX-01 and KX-02. In addition to clinical-stage development, Athenex operated commercial channels through Athenex Pharmaceutical Division (APD) and 503B compounding-related activities through Athenex Pharma Solutions (APS). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) Geographically, Athenex had a comparatively broad footprint for a mid-cap biotech, with U.S. offices and facilities in Buffalo, Clarence, Cranford, Houston, and Chicago, plus operations or offices in Hong Kong, Taipei, multiple locations in Chongqing, Manchester, Guatemala City, and Buenos Aires. That international setup supported clinical development, manufacturing, and commercial execution, but it also underscored the complexity of the organization. In competitive terms, Athenex operated in a crowded global oncology market where capital access, regulatory milestones, and trial outcomes are critical differentiators. Its positioning depended less on scale and more on whether its technology could generate clinically meaningful and approvable products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000119312519313488/d838422dex991.htm?utm_source=openai)) Recent SEC disclosures and filings show a company that had entered a difficult strategic and financial phase, with management focusing on preserving and advancing the remaining platform assets while operating under heightened uncertainty. For investors, especially French, Belgian, and Swiss readers screening Form 4 insider transactions, Athenex should be viewed as a high-risk biotech case study rather than a mature commercial pharmaceutical platform. The investment thesis historically hinged on pipeline execution, regulatory progress, and the ability to convert scientific promise into durable commercial value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1300699/000095017023008734/atnx-20221231.htm?utm_source=openai))
